In:
Cancer, Wiley, Vol. 127, No. 23 ( 2021-12), p. 4339-4347
Abstract:
Blood and Marrow Transplant Clinical Trials Network Study 1102 demonstrates superior survival for patients with high‐risk myelodysplastic syndromes undergoing allogeneic hematopoietic cell transplantation compared to nontransplant therapies. The article describes a framework to expand access to transplantation for patients with high‐risk myelodysplastic syndromes to ensure optimal implementation of the results of this study.
Type of Medium:
Online Resource
ISSN:
0008-543X
,
1097-0142
DOI:
10.1002/cncr.v127.23
Language:
English
Publisher:
Wiley
Publication Date:
2021
detail.hit.zdb_id:
1479932-7
detail.hit.zdb_id:
2599218-1
detail.hit.zdb_id:
2594979-2
detail.hit.zdb_id:
1429-1